|1.||Tollefsen, Douglas M: 7 articles (07/2011 - 01/2002)|
|2.||Matsumoto, Toshio: 5 articles (10/2012 - 06/2004)|
|3.||Akaike, Masashi: 5 articles (10/2012 - 06/2004)|
|4.||Sata, Masataka: 4 articles (10/2012 - 06/2007)|
|5.||Aihara, Ken-ichi: 4 articles (10/2012 - 06/2004)|
|6.||Ikeda, Yasumasa: 4 articles (10/2012 - 06/2004)|
|7.||Azuma, Hiroyuki: 4 articles (10/2009 - 06/2004)|
|8.||Iwase, Takashi: 3 articles (10/2012 - 06/2007)|
|9.||Vicente, Cristina P: 3 articles (07/2011 - 01/2002)|
|10.||Mourão, Paulo A S: 3 articles (05/2011 - 01/2004)|
12/01/2009 - "Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study."
10/01/2009 - "Heparin cofactor II as a novel vascular protective factor against atherosclerosis."
06/08/2004 - "Does heparin cofactor II modulate atherosclerosis and restenosis?"
12/01/2005 - "Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study."
12/15/2007 - "Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice."
01/01/2014 - "Heparin cofactor II (HCII) has recently been shown to be protective against Gram-negative infections. "
01/01/2005 - "After infection of adenovirus vector, these cells secreted heparin cofactor II protein into culture medium. "
01/01/2014 - "A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection."
01/01/2005 - "Expression of heparin cofactor II by infection of adenovirus vector inhibited thrombin-induced tissue-type plasminogen activator and interleukin-6 releases from fibroblasts and thrombin-induced interleukin-6 release from vascular smooth muscle cells. "
|3.||Septic Shock (Toxic Shock Syndrome)
04/01/2000 - "In this study, we estimated the antithrombotic effect of heparin cofactor II administered exogenously in a rat model of thrombosis. "
04/01/2006 - "We investigated whether the onset of TMA after BMT could be predicted by measuring heparin-cofactor II (HC II), a marker for thrombosis of unknown etiology. "
11/01/2002 - "To review of the state of the art relating to congenital heparin cofactor II deficiency as a potential risk factor for thrombosis, as reflected by the medical literature and the consensus opinion of recognized experts in the field, and to make recommendations for the use of laboratory assays for assessing this thrombotic risk in individual patients. "
01/01/2002 - "Heparin cofactor II inhibits arterial thrombosis after endothelial injury."
04/01/2000 - "At an effective dose in this thrombosis model, heparin cofactor II did not prolong the activated partial thromboplastin time and the prothrombin time in normal rats. "
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
09/01/1999 - "Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis."
01/01/1996 - "Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis."
06/01/1991 - "Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis."
01/01/1991 - "Recurrent venous thrombosis associated with inherited deficiency of heparin cofactor II."
10/29/1988 - "[Constitutional dysfunction of heparin cofactor II with a tendency for venous thrombosis]."
|1.||Serine Proteases (Serine Protease)
|6.||Prothrombin (Factor II)
|8.||von Willebrand Factor
|9.||antithrombin III-protease complex
|1.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)